Dipesh Uprety Highlighted Phase 3 IMforte trial on First-line Maintenance Therapy With Lurbinectedin Plus Atezolizumab in SCLC
Dipesh Uprety, Assistant Professor of Thoracic Oncology at the Barbara Ann Karmanos Cancer Institute, shared a post on X:
“IMforte: Phase 3 trial, The Lancet
– Patients with ES-SCLC were randomized to receive Lurbinectedin +atezo vs Atezo after 4 cycles of chemo-atezo
– ↑ in PFS (5.4 vs 2.1 mo) and OS (13.2 vs. 10.6 mo) with atezo + Lurbinectedin”
Title: Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial
Journal: The Lancet
Authors: Luis Paz-Ares, Hossein Borghaei, Stephen V. Liu, Solange Peters, Roy S. Herbst, Katarzyna Stencel, Margarita Majem, Mehmet Ali Nahit Şendur, Grzegorz Czyżewicz, Reyes Bernabé Caro, Ki Hyeong Lee, Melissa L. Johnson, Nuri Karadurmuş, Christian Grohé, Sofia Baka, Tibor Csőszi, Jin Seok Ahn, Raffaele Califano, Tsung-Ying Yang, Yasemin Kemal, Marcus Ballinger, Vaikunth Cuchelkar, Vilma Graupner, Ya-Chen Lin, Debasis Chakrabarti, Kamalnayan Bhatt, George Cai, Robert Iannone, Martin Reck
More posts featuring Dipesh Uprety on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023